Invivo stimulation of bone formation by aluminum and oxygen plasma surface-modified magnesium implants

Biomaterials

Volumn 34, Issue 38, 2013, Pages 9863-9876

  Wong, Hoi Man ^a,d   Zhao, Ying ^a,b,d   Tam, Vivian ^a   Wu, Shuilin ^b   Chu, Paul K ^b   Zheng, Yufeng ^c   To, Michael Kai Tsun ^a,d   Leung, Frankie K L ^a,d   Luk, Keith D K ^a   Cheung, Kenneth M C ^a   Yeung, Kelvin W K ^a,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CITY UNIVERSITY OF HONG KONG   (Hong Kong)

^c PEKING UNIVERSITY   (China)

^d THE UNIVERSITY OF HONG KONG SHENZHEN HOSPITAL   (China)

Author keywords

Cyto compatibility; Magnesium implant; Osteoblast; Plasma surface treatment

Indexed keywords

BONE-IMPLANT INTERFACES; CYTOCOMPATIBILITY; HISTOLOGICAL ANALYSIS; MICROCOMPUTED TOMOGRAPHY; OSTEOGENIC DIFFERENTIATION; PLASMA SURFACE TREATMENT; RESISTANCE PROPERTIES; SIMULATED BODY FLUIDS;

ALUMINUM; COMPUTERIZED TOMOGRAPHY; CORROSION RESISTANCE; HYDROGEN; MAGNESIUM; METAL IONS; OSTEOBLASTS; OXYGEN; PLASMAS; SCANNING ELECTRON MICROSCOPY;

BONE;

ALUMINUM; ALUMINUM OXIDE; HYDROGEN; MAGNESIUM; MAGNESIUM ION; OXYGEN;

ANIMAL CELL; ARTICLE; BONE IMPLANT; BONE MASS; IN VITRO STUDY; IN VIVO STUDY; MICRO-COMPUTED TOMOGRAPHY; NONHUMAN; OSSIFICATION; PLASMA TRANSFUSION; PRIORITY JOURNAL; ANIMAL; BONE DEVELOPMENT; CELL LINE; CELL SURVIVAL; CHEMISTRY; CYTO-COMPATIBILITY; CYTOLOGY; DRUG EFFECT; ELECTROCHEMISTRY; MAGNESIUM IMPLANT; MOUSE; OSTEOBLAST; PLASMA SURFACE TREATMENT; PROSTHESES AND ORTHOSES; SCANNING ELECTRON MICROSCOPY;

ANIMALIA;

CYTO-COMPATIBILITY; MAGNESIUM IMPLANT; OSTEOBLAST; PLASMA SURFACE TREATMENT;

ALUMINUM OXIDE; ANIMALS; CELL LINE; CELL SURVIVAL; ELECTROCHEMISTRY; MAGNESIUM; MICE; MICROSCOPY, ELECTRON, SCANNING; OSTEOBLASTS; OSTEOGENESIS; PROSTHESES AND IMPLANTS; X-RAY MICROTOMOGRAPHY;

EID: 84885373676     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.08.052     Document Type: Article

References (54)

1. Barrette-Connor E. The economic and human costs of osteoporotic fracture. Am J Med 1995, 98:3S-8S.
2. Iqbal M.M. Osteoporosis: epidemiology, diagnosis, and treatment. Southampt Med J 2000, 93:2-18.
3. Russell R.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19(6):733-759.
4. Banffy M.B., Vrahas M.S., Ready J.E., Abraham J.A. Nonoperative versus prophylactic treatment of bisphosphonate-associated femoral stress fractures. Clin Orthop Relat Res 2011, 469(7):2028-2034.
5. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. JOral Maxillofac Surg 2007, 65(3):369-376.
6. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010, 86(6):421-435.
7. Koh J.S., Goh S.K., Png M.A., Ng A.C., Howe T.S. Distribution of atypical fractures and cortical stress lesions in the femur: implications on pathophysiology. Singapore Med J 2011, 52(2):77-80.
8. Bannon M. Bisphosphonates and osteoporosis: which therapeutic agent is best?. Qjm-Int J Med 2011, 104(4):279-280.
9. Giusti A., Hamdy N.A.T., Dekkers O.M., Ramautar S.R., Dijkstra S., Papapoulos S.E. Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features. Bone 2011, 48(5):966-971.
10. Eastell R. Treatment of postmenopausal osteoporosis. NEngl J Med 1998, 338(11):736-746.
11. Baron R., Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. JClin Endocrinol Metab 2012, 97(2):311-325.
12. Kong S.W., Kim J.S., Park K.S., Cha B.H., Shim J.H., Kim J.Y., et al. Surface modification with fibrin/hyaluronic acid hydrogel on solid-free form-based scaffolds followed by BMP-2 loading to enhance bone regeneration. Bone 2011, 48(2):298-306.
13. Brown K.V., Li B., Guda T., Perrien D.S., Guelcher S.A., Wenke J.C. Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release. Tissue Eng Part A 2011, 17(13-14):1735-1746.
14. Ben-David D., Srouji S., Shapira-Schweitzer K., Kossover O., Ivanir E., Kuhn G., et al. Low dose BMP-2 treatment for bone repair using a PEGylated fibrinogen hydrogel matrix. Biomaterials 2013, 34(12):2902-2910.
15. Jun S.H., Lee E.J., Jang T.S., Kim H.E., Jang J.H., Koh Y.H. Bone morphogenic protein-2 (BMP-2) loaded hybrid coating on porous hydroxyapatite scaffolds for bone tissue engineering. JMater Sci Mater Med 2013, 24(3):773-782.
16. Jeon O., Song S.J., Yang H.S., Bhang S.H., Kang S.W., Sung M.A., et al. Long-term delivery enhances invivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. Biochem Biophys Res Commun 2008, 369(2):774-780.
17. Vo T.N., Kasper F.K., Mikos A.G. Strategies for controlled delivery of growthfactors and cells for bone regeneration. Adv Drug Deliv Rev 2012, 1292-1309.
18. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. NEngl J Med 2001, 344(19):1434-1441.
19. Lin W., Lin J. Parathyroid hormone for osteoporosis treatment. Formos J Musculoskelet Disord 2011, 2:113-117.
20. McGreevy C., Williams D. Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf 2011, 2(4):159-172.
21. Song G. Control of biodegradation of biocompatable magnesium alloys. Corros Sci 2007, 49(4):1696-1701.
22. Boccaccini A.R., Hoppe A., Guldal N.S. Areview of the biological response to ionic dissolution products from bioactive glasses and glass-ceramics. Biomaterials 2011, 32(11):2757-2774.
23. Precival M. Bone health and osteoporosis. Appl Sci Nutr 1999, 5:1-5.
24. Bigi A., Boanini E., Gazzano M. Ionic substitutions in calcium phosphates synthesized at low temperature. Acta Biomater 2010, 6(6):1882-1894.
25. Song G., Song S.A. Possible biodegradable magnesium implant material. Adv Eng Mater 2007, 298-302.
26. Zberg B., Uggowitzer P.J., Löffler J.F. MgZnCa glasses without clinically observable hydrogen evolution for biodegradable implants. Nature Mater 2009, 8:887-891.
27. Xue D., Yun Y., Tan Z., Dong Z., Schulz M. Invivo and invitro degradation behavior of magnesium alloys as biomaterials. JMater Sci Technol 2012, 28(3):261-267.
28. Witte F., Kaese V., Haferkamp H., Switzer E., Meyer-Lindenberg A., Wirth C.J., et al. Invivo corrosion of four magnesium alloys and the associated bone response. Biomaterials 2005, 26(17):3557-3563.
29. Walker J., Shadanbaz S., Kirkland N.T., Stace E., Woodfield T., Staiger M.P., et al. Magnesium alloys: predicting invivo corrosion with invitro immersion testing. JBiomed Mater Res B Appl Biomater 2012, 100(4):1134-1141.
30. Xin S.G., Song L.X., Zhao R.G., Hu X.F. Properties of aluminium oxide coating on aluminium alloy produced by micro-arc oxidation. Surf Coat Technol 2005, 199(2-3):184-188.
31. Fischer H., Niedhart C., Kaltenborn N., Prange A., Marx R., Niethard F.U., et al. Bioactivation of inert alumina ceramics by hydroxylation. Biomaterials 2005, 26(31):6151-6157.
32. Sharma V., Ranawat A.S., Rasquinha V.J., Weiskopf J., Howard H., Ranawat C.S. Revision total hip arthroplasty for ceramic head fracture a long-term follow-up. JArthroplasty 2010, 25(3):342-347.
33. Stappert C.F., Baldassarri M., Zhang Y., Hanssler F., Rekow E.D., Van P.T. Reliability and fatigue failure modes of implant-supported aluminum-oxide fixed dental prostheses. Clin Oral Implants Res 2011, 1173-1180.
34. Kim J.M., Mudgal C.S., Konopka J.F., Jupiter J.B. Complications of total elbow arthroplasty. JAm Acad Orthop Surg 2011, 19(6):328-339.
35. Anders A. Handbook of plasma immersion ion implantation and deposition 2000, Wiley, New York.
36. Cheung K.M.C., Wong H.M., Yeung K.W.K., Lam K.O., Tam V., Chu P.K., et al. Abiodegradable polymer-based coating to control the performance of magnesium alloy orthopaedic implants. Biomaterials 2010, 31(8):2084-2096.
37. Brar H.S., Platt M.O., Sarntinoranont M., Martin P.I., Manuel M.V. Magnesium as a biodegradable and bioabsorbable material for medical implants. Jom 2009, 61(9):31-34.
38. Barfield W., Colbath G., DesJardins J., An Y., Hartsock L. The potential of magnesium alloy use in orthopaedic surgery. Curr Orthop Pract 2012, 23(2):146-150.
39. Chu P.K., Tang B.Y., Cheng Y.C., Ko P.K. Principles and characteristics of a new generation plasma immersion ion implanter. Rev Sci Instrum 1997, 68(4):1866-1874.
40. 3 ceramic coating on Mg alloy. Appl Surf Sci 2007, 253(12):5306-5311.
41. 3 thin film on corrosion resistance of pure Mg and its anodic coating. Mater Sci Forum 2005, 488-489:865-868.
42. 3 coatings fabricated using plasma electrolysis. Surf Coat Technol 2002, 149(2-3):245-251.
43. Song G., Atrens A., Wu X., Zhang B. Corrosion behaviour of AZ21, AZ501 and AZ91 in sodium chloride. Corros Sci 1998, 40(10):1769-1791.
44. Wong H.M., Wu S., Chu P.K., Cheng S.H., Luk K.D., Cheung K.M.C., et al. Low-modulus Mg/PCL hybrid bone substitute for osteoporotic fracture fixation. Biomaterials 2013, 34(29):7016-7032.
45. Serre C.M., Papillard M., Chavassieux P., Voegel J.C., Boivin G. Influence of magnesium substitution on a collagen-apatite biomaterial on the production of a calcifying matrix by human osteoblasts. JBiomed Mater Res 1998, 626-633.
46. Zreiqat H., Howlett C.R., Zannettino A., Evans P., Tanzil G.S., Knabe C., et al. Mechanisms of magnesium-stimulated adhesion of osteoblastic cells to commonly used orthopaedic implants. JBiomed Mater Res 2002, 62(2):175-184.
47. Staiger M.P., Pietak A.M., Huadmai J., Dias G. Magnesium and its alloys as orthopedic biomaterials: a review. Biomaterials 2006, 27(9):1728-1734.
48. Li Z., Gu X., Lou S., Zheng Y. The development of binary Mg-Ca alloys for use as biodegradable materials within bone. Biomaterials 2008, 29(10):1329-1344.
49. Perl D.P., Moalem S. Aluminum and Alzheimer's disease, a personal perspective after 25 years. JAlzheimers Dis 2006, 9(3 Suppl.):291-300.
50. Percy M.E., Kruck T.P.A., Pogue A.I., Lukiw W.J. Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease. JInorg Biochem 2011 Nov, 105(11):1505-1512.
51. Vormann J. Magnesium: nutrition and metabolism. Mol Aspects Med 2003, 24:27-37.
52. Saris N.-E.L., Mervaala E., Karppanen H., Khawaja J.A., Lewenstam A. Magnesium: an update on physiological, clinical and analytical aspects. Clin Chim Acta 2000, 294(1-2):1-26.
53. Pybus J. Determination of calcium and magnesium in serum and urine by atomic absorption spectrophotometry. Clin Chim Acta 1968, 23(2):309-317.
54. Rettig R., Virtanen S. Composition of corrosion layers on a magnesium rare-earth alloy in simulated body fluids. JBiomed Mater Res 2009, 88A(2):359-369.